ENDV (Endonovo Therapeutics) Debt-to-Equity: -0.25 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Endonovo Therapeutics Debt-to-Equity?

Endonovo Therapeutics ENDV Debt-to-Equity is -0.25 as of Jun. 2025. Among 966 Biotechnology companies, Endonovo Therapeutics ranks worse than 103519.57% on this metric.

Endonovo Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was $6.90 Mil. Endonovo Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was $0.00 Mil. Endonovo Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2025 was $-27.82 Mil. Endonovo Therapeutics's debt to equity for the quarter that ended in Jun. 2025 was -0.25.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Endonovo Therapeutics's Debt-to-Equity or its related term are showing as below:

ENDV's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Endonovo Therapeutics  (OTCPK:ENDV) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Endonovo Therapeutics Debt-to-Equity Related Terms

Endonovo Therapeutics Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Endonovo Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endonovo Therapeutics Debt-to-Equity Chart

Endonovo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.46 -0.46 -0.22 -0.29 -0.26

Endonovo Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 -0.27 -0.26 -0.25 -0.25

ENDV vs RGBP, SIGY, CNBX: Debt-to-Equity Comparison

For the Biotechnology subindustry, Endonovo Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endonovo Therapeutics Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's Debt-to-Equity falls into.


Endonovo Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Endonovo Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(6.87 + 0) / -26.804
=-0.26

Endonovo Therapeutics's Debt to Equity Ratio for the quarter that ended in Jun. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(6.896 + 0) / -27.824
=-0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.25 mean?
Endonovo Therapeutics (ENDV) has a Debt-to-Equity of -0.25 as of Jun. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Endonovo Therapeutics and its competitors. According to the industry distribution chart, Endonovo Therapeutics ranks #999999 out of 966 companies in the Biotechnology industry.
Is Endonovo Therapeutics' Debt-to-Equity too high?
Endonovo Therapeutics' current Debt-to-Equity is -0.25. Based on the distribution chart, Endonovo Therapeutics ranks #999999 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Endonovo Therapeutics' Debt-to-Equity compare to RGBP and SIGY?
According to the Biotechnology industry distribution chart, Endonovo Therapeutics ranks #999999 out of 966 companies for Debt-to-Equity. This places Endonovo Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Endonovo Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Endonovo Therapeutics's current Debt-to-Equity is -0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current Debt-to-Equity of -0.25. The current Debt-to-Equity is -0.25. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current Debt-to-Equity is -0.25 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Endonovo Therapeutics Business Description

Address 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.